cannabidiol research psychosis

CBD For Ultra High-Risk Psychosis Patients

This study summary provides fact-based answers about CBD benefits psychosis.

  • learn how CBD is being used for Psychosis at critical risk
  • know the exact benefits of CBD for psychosis in a clinical setting
  • know the optimal oral CBD dosage tested and possible adverse effects
  • learn how CBD benefits patients at ultra-high risk for psychosis

If you don’t find an answer in this guide to a question you have, leave us a comment below. We’ll search the published studies to see if an answer exists and get back to you.

Let’s get started.

 

cbd neurological treatment

Published January 8 2020

 

 

 

 

Study Results

 

Patients at ultra-high risk for psychosis and taking 600 mg/day dose of CBD for one week exhibited an “intermediate” response for:

  • stress
  • anxiety
  • cortisol tests (a chemical measurement of response to stress). (1)

 

nih cannabidiol study

 

 

 

 

Summary

 

Control Groups

 

The intermediate response of the CBD group was in comparison to two control groups:

  • individuals not at risk for psychosis (no CBD)
  • individuals at ultra-high risk for psychosis taking placebo (no CBD) (2)

 

Testing

 

Evaluations of stress, anxiety and cortisol levels were made in the context of a high-stress environment—simulated public speaking.

 

 

Participants 

 A total of 58 individuals took part in this 1-week study.

  • 16 Ultra-High Risk For Psychosis taking 600 mg/day CBD
  • 16 Ultra-High Risk For Psychosis taking placebo (no CBD)
  • 26 Not At Risk For Psychosis (Healthy Control Group/no CBD) (3)

 

cannabidiol neurological disorder study

Evaluation Process

 

All participants were evaluated during a Trier social stress test (TSST) which is used to reliably induce stress in human study participants.

  • During the stress test, One-way analysis of variance (ANOVA) revealed that the increase in cortisol (a chemical measurement of the increase in stress) was greatest in the healthy control group (no CBD) and lowest in the high-risk placebo group (no CBD).  (4)

cbd psychosis treatment

Results

  • The high-risk group taking CBD had an increase in cortisol which fell between the healthy group (no CBD) and the placebo group (no CBD).  So,  the chemical measure of stress response for the high-risk group taking CBD showed less stress than the healthy control group but a greater stress load than the high risk for psychosis placebo control group.
  • Evaluations of cortisol reactivity were mixed as well.
  • Cannabidiol did not appear to change cortisol reactivity during the stress test of individuals at high risk for psychosis.
  • There were minimal changes in cortisol reactivity between the high-risk placebo group (no CBD) and the high-risk group who were taking CBD.
  • Changes in anxiety levels and experience of public speaking stress were most pronounced in the high-risk placebo group (No CBD) and least in the healthy control group (No CBD).
  • As with the cortisol results, the high-risk group taking CBD had an “intermediate” response which fell between the healthy control group and the high-risk placebo group. (5)

 

cbd psychosis benefit

Conclusion

 

“It is worthwhile to design further well-powered studies which investigate whether CBD may be used to affect cortisol response in clinical high risk for psychosis patients and any effect this may have on symptoms.” (6)

cannabidiol psychosis benefit

 

Interested learning about the benefits of CBD for anxiety disorders? Check out this guide.

cannabidiol guide to anxiety benefits based on latest medical studies recent to 2020

 

 

Download The CBD Research

 

Video: Dr. Gordon on CBD and Psychosis

References

Appiah-Kusi E, Petros N, Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis [published online ahead of print, 2020 Jan 8]. Psychopharmacology (Berl). 2020;10.1007/s00213-019-05442-6. doi:10.1007/s00213-019-05442-6

Study Authors 

 

Appiah-Kusi E

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

 

Petros N

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

 

Wilson R

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

 

Colizzi M

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry, Policlinico “G. B. Rossi”, University of Verona

 

Bossong MG

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

Department of Psychiatry, University Medical Centre Utrecht Brain Centre, Utrecht University

 

Valmaggia L

Department of Psychology, IoPPN, King’s College London

National Institute for Health Research, Biomedical Research Centre

 

Mondelli V

National Institute for Health Research, Biomedical Research Centre

Department of Psychological Medicine, IoPPN, King’s College London

McGuire P

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

National Institute for Health Research, Biomedical Research Centre

Bhattacharyya S

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London

National Institute for Health Research, Biomedical Research Centre

 

Keywords: Cannabidiol; Psychosis; Trier Social Stress Test; Ultra-high risk

Pin It on Pinterest

Share This